Marc Recht

Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, on the close of its $105 million Series A financing.

Cooley advised Tectonic Therapeutic, a privately held biotechnology company developing G-protein coupled receptor-targeted therapeutic proteins, on its definitive merger agreement to combine in an all-stock transaction with AVROBIO, a gene therapy company with a purpose to free people from a lifetime of genetic disease. Tectonic also obtained $130.7 million in private financing commitments with a syndicate of new and existing leading life sciences investors in connection with the merger.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Cooley advised Exscientia, a clinical-stage pharmatech company, on its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion. Lawyers Claire Keast-Butler and Tom Goodman led the Cooley team advising Exscientia.